Find a Pharmacy
Vertice Login
Info banner
A significant part of the Healthesystems vision is to create a more integrated experience for our customers

What's Happening

Stay up to date on conferences, social posts, and what’s new with Healthesystems

Events

Let’s connect at one of our upcoming conferences or speaking engagements
June 19 - Jun 20, 2025

Iowa Workers' Compensation Symposium

Healthsystems is attending the IA Workers’ Compensation Symposium, which brings together special interest groups concerned with the Iowa Workers’ Compensation Law.

Des Moines, IA
August 17 - Aug 20, 2025

WCI

Healthesystems is attending and exhibiting at the Workers’ Compensation Institute conference, which brings together workers’ compensation professionals.

Orlando, FL
View all Events

MedMonitor

An up-to-date timeline of FDA approvals that could impact workers' comp
View All MedMonitor Information

Brekiya® (dihydroergotamine mesylate) injection

Approval Date: May 2025

Note: New Product/New Formulation

While DHE has been available since 1946, this is the first DHE drug available in a ready-to-use autoinjector, indicated for the acute treatment of migraine with or without aura and the acute treatment of cluster headaches

hello world!

Yutrepia™ (treprostinil) inhalation powder

Approval Date: May 2025

Note: New Product/New Formulation

Indicated for the treatment of pulmonary arterial hypertension, this is the first and only dry-powder formulation of treprostinil

hello world!

Starjemza (Ustekinumab-hmny) injection

Approval Date: May 2025

Note: Biosimilar

A biosimilar to Stelara (ustekinumab), this drug is indicated for the treatment of moderate to severe plaque psoriasis, active psoriatic arthritis, moderate to severely active Crohn’s disease, and moderate to severely active Ulcerative Colitis

hello world!

Atzumi™ (dihydroergotamine (DHE)) nasal powder

Approval Date: Apr 2025

Note: New Product/New Formulation

While DHE has been available since 1946, this is the first DHE drug available in a nasal powder formulation and indicated for the acute treatment of migraine with or without aura

hello world!

Arbli (losartan potassium) oral suspension

Approval Date: Mar 2025

Note: New Product

Indicated for the treatment of hypertension, stroke risk reduction in patients with hypertension and left ventricular hypertrophy, and diabetic neuropathy in certain type 2 diabetes patients with hypertension

hello world!

Tyenne® (tocilizumab-aazg) injection

Approval Date: Mar 2025

Note: New Indication

A biosimilar to Acterma®, this autoimmune drug has received an additional indication for the treatment of COVID-19 in hospitalized patients who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO)

hello world!

Symbravo® (meloxicam and rizatriptan) tablets

Approval Date: Jan 2025

Note: New Product

A combination NSAID and triptan drug indicated for the acute treatment of migraine with or without aura

hello world!

Spravato® (esketamine) nasal spray, CIII

Approval Date: Jan 2025

Note: New Indication

An NMDA receptor antagonist, this drug is now indicated for use as a monotherapy for treatment-resistant depression (TRD). Spravato originally required conjunctive use with an oral antidepressant for (TRD)

hello world!

Avtozma® (tocilizumab-anoh) injection

Approval Date: Jan 2025

Note: Biosimilar

A biosimilar to Acterma, this drug is indicated for the treatment of rheumatoid arthritis, giant cell arthritis, and COVID-19 in hospitalized patients receiving supplemental oxygen and corticosteroids

hello world!

Journavx (suzetrigine) tablets

Approval Date: Jan 2025

Note: New Product

A novel, first-in-class, non-opioid analgesic indicated for the treatment of moderate to severe acute pain. Journavx targets pain-signaling pathways involving sodium channels and has not been studied for use beyond 14 days

hello world!

Victoza® (liraglutide) injection

Approval Date: Dec 2024

Note: First-Time Generic

A GLP-1 receptor agonist, this first-time generic is indicated for the once-daily treatment of type 2 diabetes, in conjunction with diet and exercise

hello world!

Steqeyma® (Ustekinumab-stba) injection

Approval Date: Dec 2024

Note: New Product

A biosimilar to Stelara®, this drug is indicated for the treatment of moderate to severe plaque psoriasis, active psoriatic arthritis, moderately to severely active Crohn’s disease, moderately to severely active ulcerative colitis

hello world!

Raldesy™ (trazodone hydrochloride) oral solution

Approval Date: Dec 2024

Note: New Formulation

An SSRI indicated for the treatment of major depressive disorder (MDD)

hello world!

Byetta® (exenatide) injection

Approval Date: Nov 2024

Note: First-Time Generic

A GLP-1 receptor agonist, this first-time generic is indicated for the treatment of type 2 diabetes, in conjunction with diet and exercise

hello world!

Otulfi™ (ustekinumab-aauz)

Approval Date: Sep 2024

Note: New Product

A biosimilar to Stelara, this drug is indicated for the treatment of moderate to severe plaque psoriasis, active psoriatic arthritis, moderate to severe Crohn’s disease, and moderate to severe ulcerative colitis

hello world!
1 2 3 10

Social Hub

Check out our latest posts and activity
View All Social Media
    lockmap-markermagnifiercrossmenucross-circle